newsfilter
← Latest News
GlobeNewswire·

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of compounds linked to a broad